Sjoerd T T Schetters

7PUBLICATIONS
84CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 30, 2026
Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling.

Karel F A Van Damme, Dorine Sichien, Katrien Van der Borght

|Aug 23, 2023
A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19.

Karel F A Van Damme, Levi Hoste, Jozefien Declercq

|May 19, 2023
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance.

Mandy van Gulijk, Anneloes van Krimpen, Sjoerd Schetters

|Jan 12, 2022
Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.

Ernesto Rodriguez, Kelly Boelaars, Kari Brown

|Jul 22, 2020
Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.

Sjoerd T T Schetters, Ernesto Rodriguez, Laura J W Kruijssen

Pageof 2